CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Medical Coverage Policy — Drug Testing (Urine/Oral Fluid)

Defines coverage, documentation, and frequency criteria for presumptive (immunoassay) and definitive (confirmatory) urine/oral fluid drug testing for Commercial products of BCBS Rhode Island.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyDrug Testing (Urine/Oral Fluid) — presumptive and definitive coverage criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionOrder presumptive testing when rapid screening is required and document medical necessity and clinician orders in the medical record.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

80305–80307Covered CPT examples

1–3/weekPresumptive UDT freq

≤1/weekDefinitive UDT freq

80320–80377, 83992Invalid codes (denied)

per date of serviceReporting basis

Presumptive Testing Coverage

Presumptive testing is covered when ALL of the following are met:

Presumptive UDT coverage: Ordered by the clinician when it is necessary to rapidly obtain and/or integrate results into clinical assessment and treatment decisions

Presumptive=immunoassay qualitative screening

Definitive Testing Coverage

Definitive UDT is reasonable and necessary when ANY of the following apply (examples listed):

Definitive UDT indications: Identify a specific substance or metabolite that is inadequately detected by a presumptive UDT

Definitive testing methods include GC-MS, LC-MS/MS

Definitive UDT indications: Definitively identify specific drugs in a large family of drugs

Definitive UDT indications: Obtain a definitive concentration of a drug when needed for management (for example to assess continuation of use per a treatment plan)

Definitive UDT indications: Identify specific substances or metabolites not detected by presumptive UDT (e.g., fentanyl, meperidine, synthetic cannabinoids and other synthetic/analog drugs)

Definitive UDT indications: Confirm or refute a presumptive UDT result that is inconsistent with self-report, presentation, medical history, or current prescribed medication plan

Definitive UDT indications: Rule out an error as the cause of an unexpected result

Definitive UDT indications: Identify non‑prescribed medication or illicit use to guide safe prescribing of controlled substances

Definitive UDT indications: Use in differential assessment of medication efficacy, side effects, or drug‑drug interactions; consider full panel definitive testing when initial evaluation or patient behavior suggests use not identified on presumptive testing

Frequency Limits for SUD Monitoring

Frequency criteria (SUD monitoring) — coverage when documented and within these limits:

Presumptive UDT frequency: 0–30 days abstinence: 1–3 presumptive UDT per week; 31–90 days: 1–3 presumptive UDT per week; >90 days: 1–3 presumptive UDT per month<=3 per week or month depending on stage

More than 3 in the respective period is not reasonable and necessary and not allowed; frequency must be documented in the medical record

Definitive UDT frequency: 0–30 days abstinence: not to exceed 1 physician‑directed definitive profile per week; 31–90 days: 1–3 physician‑directed definitive profiles per month; >90 days: 1–3 physician‑directed definitive profiles per three monthsspecific caps per stage

Exceeding the stated caps is not reasonable and necessary and not allowed; rationale and frequency must be documented in the medical record

Testing that is performed solely because a member is participating in an inpatient or intermediate substance use disorder (SUD) program, performed under blanket or routine/standing orders, or ordered only to satisfy third‑party requirements (for example employment or medicolegal purposes) is considered not eligible for reimbursement. Documentation in the medical record must show individualized clinician ordering and medical necessity for each test; routine testing at every visit, blanket orders, or standing orders without individualized clinician decision making are not reasonable and may be denied. Reference laboratories that reflex to definitive methods must have a specific physician order to perform the reflex; reflexive definitive testing without clinician direction is not considered reasonable in many circumstances and may be denied.

The CPT code range 80320–80377 and 83992 are explicitly stated as invalid for BlueCHiP for Medicare and BCBSRI Commercial products and will be denied. Claims for definitive testing should be submitted using the appropriate HCPCS/G‑codes listed in the policy (for example G0481–G0483, G0659) rather than the invalid CPT codes.

All indications for definitive testing that are not specifically listed in this policy are considered not medically necessary. In addition, reflexive definitive urine drug testing performed without a specific clinician order (for example, automatic reflex from a point‑of‑care presumptive IA without clinician direction) is generally not covered; if the clinician requires confirmation they must specifically order the definitive test and documentation must support the clinical rationale.

Covered Indications

Clinical management

Clinical management — guidance on when rapid screening (presumptive) is appropriate and when identification/quantification (definitive) is required; reflex testing rules described.

When presumptive testing is appropriate: When a clinician requires rapid screening results to inform assessment and treatment decisions (presumptive immunoassay)

Presumptive tests performed to rapidly inform care; documentation of order and rationale required

When definitive testing is required: When identification or quantification of specific substances/metabolites is necessary for clinical management, including cases where presumptive tests do not detect the analyte of interest or when results are inconsistent with clinical information

Definitive methods include GC‑MS or LC‑MS/MS; clinician‑directed ordering and documentation required

Reflex testing by reference laboratories: Reference laboratories may reflex to definitive methods to verify a presumptive positive before reporting to the ordering clinician under specified circumstances

Reflex testing must meet the policy's specified circumstances and be documented; reflex without clinician order may be denied in many contexts

Drug testing for detection and identification

Drug testing for detection and identification — definitive methods and specimen validity testing requirements.

Definitive method requirements: Definitive drug testing must utilize identification methods able to identify individual drugs and distinguish structural isomers (e.g., GC‑MS, LC‑MS/MS) and include use of stable isotope or other recognized internal standards, method‑ or drug‑specific calibration, and matrix‑matched quality control material

Qualitative or quantitative methods; required quality controls and standards as specified in code descriptors

Specimen validity testing: Definitive testing includes specimen validity testing (e.g., as described in code descriptors); specimen validity components are not to be billed separately when included in the test code

Do not bill separate specimen validity tests in addition to covered testing codes

Coding and reporting: Definitive testing should be reported using the appropriate CPT/HCPCS/G‑codes (e.g., 80307, G0481, G0482, G0483) per the number of drug classes analyzed and method requirements

Certain CPT codes (80320‑80377, 83992) are invalid for BCBSRI and will be denied; use appropriate HCPCS/G‑codes for definitive testing

Frequency Limits

Presumptive UDT frequency limits (SUD monitoring)

0–30 days abstinence1–3 presumptive UDT per week; >3 per week is not reasonable and necessary

31–90 days abstinence1–3 presumptive UDT per week; >3 per week is not reasonable and necessary

>90 days abstinence1–3 presumptive UDT per month; >3 per month is not reasonable and necessary

Definitive UDT frequency limits (SUD monitoring)

0–30 days abstinenceDefinitive UDT: not to exceed 1 physician-directed definitive profile per week

31–90 days abstinenceDefinitive UDT: 1–3 physician-directed definitive profiles per month; >3 per month not allowed

>90 days abstinenceDefinitive UDT: 1–3 physician-directed definitive profiles per three months; >3 per 3 months not allowed

Presumptive and definitive drug test codes and reporting basis

Per date of service / per day reporting80305, 80306, 80307: code descriptors specify billing per date of service; G0659: per day; G0481/G0482/G0483: per profile class counts

Presumptive direct observation80305 — presumptive tests read by direct observation, includes sample validation when performed, billed per date of service

Presumptive instrument-assisted80306 — presumptive tests read by instrument-assisted direct observation, includes sample validation when performed, billed per date of service

Definitive (1–7 classes)80307 — definitive tests (GC/MS, LC/MS etc.), includes specimen validity testing, billed per 1–7 drug classes

Definitive (8–14 classes)G0481 — definitive testing per 8–14 drug classes, includes specimen validity testing

Definitive (15–21+ classes)G0482 / G0483 — definitive testing per 15–21+ drug classes, includes specimen validity testing

Coding and Billing Codes

Covered CPT Codes - Presumptive (direct observation)CPTCovered

80305

test(s) , presumptive; any number of classes, any number of devices Or procedures; of read by direct observation only (eg, utilizing immunoassay [eg, dipsticks, cups, cards, Or cartridges]), includes sample validation when performed, per date of service

Covered CPT Codes - Presumptive (instrument assisted)CPTCovered

80306

test(s), presumptive, any number of drug classes, any number of devices Or procedures; read by instrument assisted direct observation (eg, utilizing immunoassay [eg, dipsticks, cups, cards, or cartridges]), includes sample validation when performed, per date of service

Covered CPT Codes - Definitive (confirmatory)CPTCovered

80307

test(s), presumptive, any number of classes, any number of devices Or procedures; by instrument chemistry analyzers ... includes specimen validity testing, per 1-7 drug class(es) ... definitive, utilizing identification methods able to identify individual and distinguish between structural isomers ... qualitative Or quantitative, all sources, includes specimen validity testing, per 1-7 drug class(es)

Presumptive drug testing CPTCPTCovered

80306

Presumptive/definitive mixed CPTCPTCovered

80307

test(s), presumptive or definitive by instrument chemistry analyzers or definitive methods; includes specimen validity testing, per 1-7 drug class(es)

HCPCS G-codes definitive testing (8-14 classes)HCPCSCovered

G0481

test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers ... qualitative Or quantitative, all sources, includes specimen validity testing, per 8-14 drug class(es), including metabolite(s) if performed

HCPCS G-codes definitive testing (15-21+ classes)HCPCSCovered

G0482	test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers ... includes specimen validity testing, per 15-21 drug class(es), including metabolite(s) if performed
G0483	test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers ... includes specimen validity testing, per more class(es), including metabolite(s) if performed

HCPCS G-code for definitive testing without full calibration/QC/standardsHCPCS

G0659

test(s), definitive, ... performed without method Or specific calibration, without matrix-matched quality control material, Or without use of stable isotope Or other universally recognized internal standard(s) ... qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of classes

Invalid CPT codes for BCBSRICPTNot Covered

80320-80377	CPT code range stated as invalid for BlueCHiP for Medicare and Commercial products
83992	CPT code stated as invalid for BlueCHiP for Medicare and Commercial products

Sample validation billing guidance

Do not bill separate specimen validity testsCode descriptions for 80305/80306/80307 include sample validation when performed; do not bill creatinine, pH, specific gravity, oxidants, or similar separately in addition to these testing codes

Sample validation included in presumptive codes80305 and 80306 descriptions state ‘includes sample validation when performed’ (per date of service)

Sample validation included in definitive code80307 description includes specimen validity testing when performed (per 1–7 drug classes)

Drug class count per code

80307Definitive or mixed test billed per 1–7 drug classes

G0481Definitive testing per 8–14 drug classes

G0482 / G0483Definitive testing per 15–21 (and more) drug classes

Provider Actions and Billing Guidance

Prior Authorization

Not applicable

Billing Rule

Billing: Use HCPCS/G‑codes for Definitive Testing

Definitive (confirmatory) testing must be billed using the appropriate HCPCS/G‑codes (e.g., G0480–G0483, G0659) for definitive urine drug testing. CPT codes in the range 80320–80377 and CPT 83992 are invalid for BCBSRI Medicare and Commercial products and will be denied; submit definitive testing using the correct HCPCS/G‑codes.

Use HCPCS/G‑codes for definitive testing (e.g., G0480–G0483, G0659)
Do not bill CPT 80320–80377 or 83992 — these codes will be denied

Denial Risk

Reflex Definitive UDT Without Clinician Order — Denial Risk

Reflex definitive UDT (confirmatory testing performed automatically by a reference laboratory without a specific clinician order for the definitive test) is not reasonable and necessary when presumptive testing is performed at the point of care and the clinician has adequate information to manage the patient. If the clinician is not satisfied with a presumptive result, the clinician must specifically order the subsequent definitive test. Reflex testing performed without a clinician’s specific order may be denied.

Reflex definitive testing without a clinician’s specific order risks denial
If clinician needs confirmation, they must place an explicit order for definitive testing

Denial Risk

Routine/Blanket Orders and Inpatient/Programmatic Testing Not Covered

Routine or blanket testing (for example, testing at every visit, standing orders for all patients, or testing required solely to satisfy a third party) is not reasonable and necessary and is not eligible for reimbursement. Reference laboratories and clinicians should not rely on blanket or standing orders to perform reflex definitive testing.

Routine testing (e.g., testing at every visit) is not covered
Blanket orders or standing orders for all patients are not covered
Testing done solely to meet third‑party requirements is not covered

Documentation Required

Reflex Testing Documentation

Reference laboratories may reflex presumptive positives to definitive methods (e.g., GC‑MS or LC‑MS/MS) to verify presumptive positive results before reporting to the ordering clinician when they cannot access patient‑specific clinical information. However, reflex testing must follow the policy’s conditions and documentation expectations. When reflex testing is performed, laboratories should document the reason for reflex and the method used.

Reference labs may reflex to definitive methods to confirm presumptive positives when clinically appropriate
Document rationale and methods used for any reflex testing performed by the laboratory

Documentation Required

Definitive Test Method and Documentation Requirements

Definitive test methods must include specimen validity testing and use identification methods capable of distinguishing individual drugs and structural isomers (e.g., GC‑MS, LC‑MS/MS). Methods should use stable isotope or other recognized internal standards and matrix‑matched quality control material; method‑ or drug‑specific calibration and QC must be documented. The medical record must include a clinician order, the rationale for testing, the individualized panel or drugs ordered, testing frequency based on treatment stage, and results used to direct care.

Definitive methods: GC‑MS or LC‑MS/MS (qualitative or quantitative) with specimen validity testing
Use stable isotope/internal standards and matrix‑matched QC; document calibration and QC procedures
Medical record must contain clinician order, rationale, individualized panel, frequency rationale, and results

Ordering Requirements

Note

Clinician must order and individualize definitive profiles

Order tests only when a clinician has evaluated the patient and documented the clinical need; physician‑directed definitive profiles must be individualized and ordered for each patient based on history and risk.

Individualize physician‑directed definitive profiles by patient.
Document the clinical rationale and history supporting each definitive profile order.

Billing Rule

Verify member benefits and eligibility before testing

Verify member benefits and eligibility per the member's subscriber certificate or employer agreement before performing testing; benefits and eligibility supersede this policy and providers should confirm coverage for the specific patient.

Confirm member‑specific coverage and any benefit limitations prior to testing.
Do not bill members for non‑covered services unless agreed in writing in advance.

Definitions

Presumptive testing (IA) definition

DefinitionImmunoassay (IA) presumptive testing: qualitative screening intended to rapidly obtain results to inform clinical assessment and treatment decisions

PurposeUsed when rapid screening is necessary to integrate results into care and guide immediate decisions

ScopeApplies to urine and oral fluid presumptive IA methods as described in policy

Definitive testing (confirmatory) definition

DefinitionDefinitive (confirmatory) testing: quantitative or qualitative testing using identification methods (e.g., GC/MS, LC/MS/MS) to identify specific drugs and metabolites and quantify when clinically necessary

Methods requiredIncludes methods able to identify individual drugs and distinguish structural isomers and requires calibration, stable isotope/internal standards, and matrix-matched QC for many HCPCS codes

Use casesUsed to verify presumptive positives, identify substances not detected by presumptive testing, or resolve inconsistent results

Presumptive drug test (instrument-assisted) definition

Example methods/devicesInstrument-assisted direct observation immunoassay methods (e.g., dipsticks, cups, cards, cartridges) used for presumptive screening

Billing note80306 describes instrument-assisted presumptive testing and includes sample validation when performed, billed per date of service

Operational useTypically performed to rapidly obtain results and may be used in clinician-directed screening workflows

Definitive drug test definition

Analytical capabilityDefinitive drug tests use analytical methods (GC/MS, LC/MS single or tandem) able to identify individual drugs and distinguish structural isomers; immunoassays and certain enzymatic methods are excluded

Quality requirementsMany HCPCS/G-codes require stable isotope or other recognized internal standards, method- or drug-specific calibration, and matrix-matched quality control material

Includes specimen validity testingDefinitive codes (G0481–G0483, 80307) include specimen validity testing when performed

Background

Presumptive urine/oral fluid drug testing (immunoassay) provides rapid qualitative screening to inform immediate clinical decisions and is recorded as per‑date‑of‑service screening; instrument‑assisted or direct observation IA methods (eg, dipsticks, cups, cards, cartridges) are described by the presumptive CPT codes and include sample validation when performed. Definitive (confirmatory) testing uses identification methods such as GC‑MS or LC‑MS/MS to identify specific drugs and metabolites and may quantify results when clinically necessary; definitive methods must include specimen validity assessment and, for many HCPCS/G‑codes, appropriate method‑ or drug‑specific calibration, use of stable isotope or other recognized internal standards, and matrix‑matched quality control materials. Medical records must document clinician orders, medical necessity, rationale for the tests ordered, and frequency tied to the stage of treatment or monitoring.

OpenPayer